|
May 25 |
PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA...
Interim data being presented at ASCO 2023 Annual... |
|
May 18 |
PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Ad...
Company plans to initiate VERSATILE-003 Phase 3... |
|
May 15 |
PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results...
Updated data from VERSATILE-002 Phase 2 trial to be... |
|
May 04 |
PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results...
FLORHAM PARK, N.J., May 04, 2023 (GLOBE... |
|
Apr 27 |
PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Com...
Abstract selected as featured poster to be... |
|
Apr 24 |
PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Deve...
FLORHAM PARK, N.J., April 24, 2023 (GLOBE... |
|
Apr 12 |
PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023...
FLORHAM PARK, N.J., April 12, 2023 (GLOBE... |
|
Apr 03 |
PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week f...
PDS Biotech prepares to advance PDS0101 into a... |
|
Mar 30 |
PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck ...
Company has completed Phase 3 manufacturing of... |
|
Mar 29 |
PDS Biotech to Participate in Cantor’s Future of Oncology Virtual Symposium ...
FLORHAM PARK, N.J., March 29, 2023 (GLOBE... |
|
Mar 28 |
PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results...
Successful meeting with FDA to discuss... |
|
Mar 16 |
PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results...
FLORHAM PARK, N.J., March 16, 2023 (GLOBE... |
|
Mar 07 |
PDS Biotech to Participate at 33rd Annual Oppenheimer Healthcare Conference...
FLORHAM PARK, N.J., March 07, 2023 (GLOBE... |
|
Mar 01 |
PDS Biotech Announces the Publication of PDS0301 Study Linking Induced Changes in Immune Responses with Clinical Outcome...
National Cancer Institute (NCI)-led research of... |
|
Feb 27 |
PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Che...
Received guidance on registrational path for... |
|
Feb 16 |
PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by ...
Infectimune™ (R-DOTAP) nanoparticles... |
|
Feb 08 |
PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection...
Infectimune™ induced neutralizing antibody and... |
|
Feb 06 |
PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress...
Abstract, titled “HPV16-specific CD4 and CD8 T... |
|
Jan 26 |
PDS Biotech Announces Participation in the Channelchek Takeaway Series...
FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE... |
|
Jan 13 |
PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference...
FLORHAM PARK, N.J., Jan. 13, 2023 (GLOBE... |
|
Jan 03 |
PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KG...
PDS Biotech bolsters immuno-oncology portfolio with a... |
